Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Bringing state-of-the-art healthcare to Florida heart patients
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.
Cardiologists make case against routine interventions for asymptomatic severe AS
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.

FDA grants new valve-in-valve TAVR offering its breakthrough device designation

The new device was designed to help clinicians perform valve-in-valve TAVR on certain high-risk patients. One cardiologist familiar with the technology said it could be easily added to any preexisting TAVR workflow.

older patient with a doctor at their house

Valve-in-valve TAVR with Medtronic’s CoreValve devices still safe and effective after 5 years

Researchers tracked five-year data from more than 200 patients, sharing their findings in the American Journal of Cardiology.

weight loss scale overweight obese lose weight pounds

TAVR in patients with severe obesity: Longer hospital stays, higher costs, more health risks

The CDC defines severe obesity, or class III obesity, as any patient with a BMI of 40 or higher. TAVR among these patients is not associated with a lower survival rate, but it does lead to many more risks.

ICE-guided Watchman procedures linked to safety concerns—is TEE better for LAAO or will things improve?

TEE and ICE are each associated with certain advantages and disadvantages, researchers explained. The new analysis included data from nearly 40,000 patients.

Integer acquires medical device specialists with experience in structural heart, electrophysiology for $140M

Integer's estimated 2023 sales nearly reached $1.6 billion, up 16% compared to 2022. According to the company's statement, this acquisition helps expand its footprint in several key markets.

ICE guidance reduces risk of permanent pacemaker implantation after TAVR with a self-expandable valve

Heart teams can limit the risk of conduction disturbances that lead to permanent pacemaker implantation by utilizing both the cusp-overlap method and intracardiac echocardiography.

Valve-in-valve TAVR an effective tool for treating structural valve degeneration after SAVR

With heart teams performing valve-in-valve TAVR more and more, researchers wanted to take a fresh look at patient outcomes. Overall, they found, the procedure was linked to a low mortality rate and fewer permanent pacemakers than native-valve TAVR.

Preventing blood clots after TMVR—what is the best anticoagulant for the job?

Choosing between DOACs and VKAs could make a significant impact on patient outcomes, according to new findings published in the Journal of the American College of Cardiology.

Structural Heart Disease

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Bringing state-of-the-art healthcare to Florida heart patients

Cardiologists make case against routine interventions for asymptomatic severe AS